Trials / Unknown
UnknownNCT06101316
A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Shanghai Zhimeng Biopharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
CB06-036 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CB06-036 | CB06-036 Capsule |
Timeline
- Start date
- 2023-09-19
- Primary completion
- 2023-10-30
- Completion
- 2023-12-29
- First posted
- 2023-10-26
- Last updated
- 2023-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06101316. Inclusion in this directory is not an endorsement.